Business Wire

24,000 Registered Attendees Fill the Halls of Successful SPIE Photonics West 2025

10.2.2025 20:55:00 CET | Business Wire | Press release

Share

The largest annual optics and photonics event of the year highlighted exciting new research, networking, and the latest in photonics products and industry trends

SPIE, the international society for optics and photonics, registered 24,000 optics and photonics professionals from over 75countries for Photonics West, as the Society hosted the largest international annual photonics meeting at San Francisco’s Moscone Center. The dynamic week, which ran from 25 to 30 January, featured 1,588 exhibitors and 5,000 technical presentations across four focused tracks – BiOS, LASE, OPTO, Quantum West – four exhibitions, and the co-located AR | VR | MR conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210056991/en/

null

SPIE Photonics West 2025 exhibition opens for business at San Francisco's Moscone Center. (Photo: Business Wire)

“Photonics West marks the start of the optics and photonics calendar every year,” said SPIE CEO Kent Rochford. “And this year, it also marked a truly exciting milestone for SPIE as the Society’s Membership surpassed 25,000! In addition, our newest conference, Quantum West, continues to grow, reflecting the ongoing development of this exciting technological area and its many applications. Throughout the week, Photonics West 2025 proved to be a terrific meeting of minds, showcasing the varied ways optics and photonics technologies are impacting our lives, and now I’m looking forward to Photonics West 2026, an event which is already in the works.”

As always, the action-filled week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. More than 100 technical conferences complemented the four exhibitions, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.

The SPIE Industry Program continues to highlight key and critical areas. The SPIE Global Business Forum – which brings together top industry executives for high-level presentations, networking, and conversations – was once again a sold-out success. The glamorous Prism Awards, now in its 17th year, celebrated the best new optics and photonics products, while the inspiring Startup Challenge pitch competition recognized three exciting emerging photonics companies. And at the Quantum West Business Summit, speakers and panelists discussed the current trends in this rapidly growing technical and commercial arena.

In addition, 52 educational courses offered expert-led technical training and learning, complementing the many various professional development and networking opportunities on offer throughout the week: From the Lunchtime Professional Development Education series to social events, Photonics West featured a packed calendar of meet-ups, canine-focused relaxation time, and interactive, collaborative gatherings. And in conjunction with Photonics West, SPIE celebrated 20 years of its Women in Optics notebook, bringing together such luminaries as Ursula Keller, Muyinatu "Bisi" Bell, and Jessica Wade for a day-long event of speakers, panelists, and conversations.

While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions – BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the AR | VR | MR exhibition – that best showcased the increasingly critical photonics industry and the importance of in-person meetings.

“We started out very fast, very busy right off the jump,” said Optikos Director of Operations Dennis Fantone. “It’s been really exciting connecting with old colleagues and friends that hadn’t been to the show before or hadn’t been in a few years. And this is also a great place to meet up not just with customers but with vendors as well: It’s great to get the personal touch that you just get over email and phone.”

“We’ve had really good traffic and have been able to see old customers and suppliers as well as making new contacts,” said Wasatch Photonics Senior Optical Engineer Elroy Pearson. “Photonics West has been really fruitful.”

“I’ve been going to Photonics West ever since it was a tiny, tiny show in San Jose,” said NKT President and CEO Basil Garabet. “We like this show – for us it’s the big show in the US. And because we are very much into the medical and bio area, being at BiOS as well is good for us. We like the position we’re in on the show floor because we don’t have to move – so that works really well for us: we just set up one booth for both shows. Now we are part of Hamamatsu, and they are right across the way, so again that’s worked out really well for us. It’s altogether good, and we look forward to it when we come over. It’s been a very good week.”

“Photonics West 2025 has highlighted the industry’s strong focus on precision, integration, and scalability in optical and photonic technologies,” noted Dr. Efstratios (Stratos) Kehayas, President, Photonics at G&H. “We’ve seen significant interest in advanced laser beam shaping, integrated photonics for compact systems, and high-reliability optical components for demanding applications in industrial, laser fusion and life sciences. The conversations at our booth reflect a growing demand for solutions that enhance performance while addressing challenges in power efficiency, miniaturization, and system integration.”

During the Photonics West week, SPIE also announced its latest SPIE Endowment Matching Program partnerships, one with Boston University and another with National University of Singapore.

As SPIE Director of Sales Jeff Nichols points out, even after this exciting week, there’s so much to look forward to. “The week of Photonics West has always been the best place to see the size and scope of our industry,” notes Nichols. “And in 2026, we're thrilled to be adding VisionTech, a new exhibit and technical program that will showcase the photonics technologies enabling the imaging and vision markets. With the continued growth of Photonics West, SPIE is turning San Francisco in January into a single stop for anyone interested in the latest advancements in photonics technologies and the numerous applications that they enable.”

SPIE Photonics West 2026 will take place 17-22 January at the Moscone Center in San Francisco. The call for papers for the 2026 event will open in Spring of 2025.

About SPIE

SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, we have invested more than $25 million in the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210056991/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye